根据弗若斯特沙利文的资料，觅瑞集团是开发及商业化用于癌症及其他疾病早期检测的、精准的、无创的、可负担的、基于血液的miRNA检测试剂盒的先驱者与领导者。公司是全球为数不多的已获得分子癌症筛查行业*IVD产品监管批准的公司之一，同时也是全球范围内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。According to the Hong Kong Stock Exchange's disclosure on November 4, Mirxes Holding Company Limited (Mirxes Holding Company Limited) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC (CICC) and CCBI (CCBI) as co-sponsors. The company submitted two listing applications to the Hong Kong Stock Exchange on July 25, 2023 and April 30 this year.
The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on November 4, Mirxes Holding Company Limited (Mirxes Holding Company Limited) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC (CICC) and CCBI (CCBI) as co-sponsors. The company submitted two listing applications to the Hong Kong Stock Exchange on July 25, 2023 and April 30 this year.
According to the prospectus, Mirui Group, founded in 2014, is a microribonucleic acid (miRNA) technology company originating in Singapore, focusing on popularizing disease screening and diagnosis solutions around the world. As of October 31, 2024, the company has one core product (i.e. GastroClearTM), two other commercial products (i.e. LungClearTM and FortitudeTM), and six pre-clinical candidate products. The company's core product, GastroClearTM, is a blood-based miRNA test set composed of 12 miRNA biomarkers for gastric cancer screening. GastroClearTM was successfully commercialized after obtaining a Class C in vitro diagnostic (IVD) certificate from the Singapore Health Sciences Authority (HSA) in May 2019.
According to Frost & Sullivan, Mirui Group is a pioneer and leader in developing and commercializing accurate, non-invasive, affordable, blood-based miRNA testing kits for early detection of cancer and other diseases. The company is one of the few companies in the world that has obtained regulatory approval for IVD products in the molecular cancer screening industry*. It is also the first and only company in the world to obtain regulatory approval for molecular gastric cancer screening IVD products.
In the early detection business segment, Minrui Group's top priority is to develop, produce and commercialize miRNA early detection kit products that can enter the mass market. These test kit products are in the form of simple blood tests performed on PCR instruments to detect miRNA biomarkers associated with various diseases. Under the early detection business segment, as of October 31, 2024, the company had one core product (i.e. GastroClearTM), another commercial product, and six pre-clinical candidate products.
In the Precision Multiomics business segment, Mirui Group focuses on providing complex, miRNA-centered multiomics testing solutions for biopharmaceutical companies, government agencies, and academic and clinical institutions. In addition, the company is also collaborating with partners to develop next-generation high-complexity diagnostic applications to discover novel biomarkers in the form of various diseases and help discover candidate therapies. These activities support the company to develop a comprehensive portfolio of intellectual property and diagnostic solutions for clinical customers and partners, enabling them to remain competitive in the cancer care industry.
The Early Detection and Precision Multiomics business division of Minrui Group is complemented by the Infectious Diseases Business Division. In this business division, the company has developed, produced and deployed FortitudeTM COVID-19 diagnostic kits for about 35 countries during the pandemic.
On the financial side, in 2021, 2022, 2023, and 2024, for the six months ended June 30, Mirui Group achieved revenue of approximately USD 60.6498 million, 17.759 million yuan, 24.185 million yuan, and 9.5668 million yuan, respectively. Losses during the same period were approximately USD 3.0811 million, 56.2027 million yuan, 69.5693 million yuan, and 44.3259 million yuan million yuan.
